Clinical trials: Anaphylactic Reaction
- Condition Anaphylactic Reaction
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Pompe Disease
Alglucosidase Alfa Pompe Safety Sub-Registry
To collect uniform and meaningful data on patients with Pompe disease who experience anaphylaxis, severe allergic reactions, and/or signals of severe cutaneous and/or systemic immune complex-mediated reactions following treatment…
- Trial name
- NCT01710813
- Testing
- alglucosidase alfa
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 110 people
- Sponsor
- Genzyme, a Sanofi Company
Food Hypersensitivity, Anaphylaxis
A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel).
- Trial name
- NCT07027163
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Asthma
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
This study will establish a clinical data and serum repository of anaphylaxis cases associated with Xolair administration and control patients who have received Xolair without associated anaphylaxis.
- Trial name
- X-PAND (NCT00813748)
- Testing
- Xolair
- Where
- 7 sites in United States
- Volunteers
- 118 people
- Sponsor
- Genentech, Inc.
Epinephrine, Hypersensitivity, Immediate
Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients
This Phase 2, open-label, single-arm study will evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of a single dose of epinephrine nasal spray (ENS) in children and adolescents 2 to 17 years of age with a…
- Conditions
- Epinephrine, Hypersensitivity, Immediate, Anaphylaxis
- Trial name
- NCT07891780
- Testing
- Epinephrine Nasal Spray, 2.5 mg, Epinephrine Nasal Spray, 5.25 mg
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Hikma Pharmaceuticals USA Inc.
Anaphylaxis
Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis
Anaphylaxis is an acute serious allergic reaction, with multi-organ system manifestations caused by the release of chemical mediators and it is potentially fatal .
- Trial name
- NCT03523221
- Testing
- Dexamethasone Oral
- Where
- Qatar
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Hypersensitivity
Coreg and HSRs-Updated Analysis
A cluster of reports of hypersensitivity reactions among patients who switched from carvedilol (immediate release formulation, referred to hereafter as carvedilol) to carvedilol extended release was received during the initial…
- Trial name
- NCT01316952
- Testing
- Carvedilol immediate release only, Carvedilol extended release only, Long acting β-blockers
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Peanut Allergy, Peanut Hypersensitivity
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with…
- Conditions
- Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
- Trial name
- NCT05621317
- Testing
- PVX-108
- Where
- 14 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Aravax Pty Ltd